Fabry Disease Treatment

Fabry Disease Treatment

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Fabry Disease Treatment</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">eGFR</td>
<td>Every 6-12 months</td>
</tr>
<tr>
<td class="label">Proteinuria</td>
<td>Every 6-12 months</td>
</tr>
<tr>
<td class="label">Cardiac MRI</td>
<td>Every 2-3 years</td>
</tr>
<tr>
<td class="label">Echocardiogram</td>
<td>Annually</td>
</tr>
<tr>
<td class="label">ECG/Holter</td>
<td>Annually</td>
</tr>
<tr>
<td class="label">Lyso-Gb3</td>
<td>Every 1-2 years</td>
</tr>
<tr>
<td class="label">Neurological assessment</td>
<td>Annually</td>
</tr>
</table>

Fabry disease (Anderson-Fabry disease) is an X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (α-Gal A), leading to accumulation of globotriaosylceramide (Gb3/GL-3) in various tissues throughout the body[@germain2010]. The disease affects multiple organ systems including the kidneys, heart, nervous system, and skin. Treatment strategies for Fabry disease have evolved significantly over the past two decades, now encompassing disease-specific therapies, symptomatic management, and emerging approaches.

Disease-Modifying Therapies

Enzyme Replacement Therapy (ERT)

Fabry Disease Treatment

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Fabry Disease Treatment</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">eGFR</td>
<td>Every 6-12 months</td>
</tr>
<tr>
<td class="label">Proteinuria</td>
<td>Every 6-12 months</td>
</tr>
<tr>
<td class="label">Cardiac MRI</td>
<td>Every 2-3 years</td>
</tr>
<tr>
<td class="label">Echocardiogram</td>
<td>Annually</td>
</tr>
<tr>
<td class="label">ECG/Holter</td>
<td>Annually</td>
</tr>
<tr>
<td class="label">Lyso-Gb3</td>
<td>Every 1-2 years</td>
</tr>
<tr>
<td class="label">Neurological assessment</td>
<td>Annually</td>
</tr>
</table>

Fabry disease (Anderson-Fabry disease) is an X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (α-Gal A), leading to accumulation of globotriaosylceramide (Gb3/GL-3) in various tissues throughout the body[@germain2010]. The disease affects multiple organ systems including the kidneys, heart, nervous system, and skin. Treatment strategies for Fabry disease have evolved significantly over the past two decades, now encompassing disease-specific therapies, symptomatic management, and emerging approaches.

Disease-Modifying Therapies

Enzyme Replacement Therapy (ERT)

Enzyme replacement therapy remains the cornerstone of Fabry disease treatment, providing exogenous α-Gal A to reduce substrate accumulation[@schiffmann2001].

Agalsidase Alfa (Replagal)

• Manufacturer: Takeda (formerly Shire)
• Dose: 0.2 mg/kg body weight every other week via intravenous infusion
• Infusion time: Approximately 40 minutes
• Efficacy: Demonstrated reduction in Gb3 accumulation in renal podocytes, endothelial cells, and myocardial cells; stabilization of renal function; reduction in cardiac mass; improvement in neuropathic pain and quality of life[@eng2006]
• Immunogenicity: Approximately 50-70% of patients develop anti-drug antibodies, which may reduce efficacy in some patients

Agalsidase Beta (Fabrazyme)

• Manufacturer: Sanofi Genzyme
• Dose: 1 mg/kg body weight every other week via intravenous infusion
• Infusion time: Approximately 1-2 hours
• Efficacy: Similar to agalsidase alfa in reducing substrate burden and stabilizing organ function; approved for patients with confirmed Fabry disease[@fabrazyme]
• Immunogenicity: Similar antibody development rates as agalsidase alfa

Comparative Considerations

Both ERT formulations have demonstrated similar clinical outcomes in head-to-head comparisons[@vedder2007]. The choice between formulations may depend on:

• Payer coverage and reimbursement
• Infusion tolerability
• Antibody status
• Patient preference for infusion duration

Pharmacological Chaperone Therapy

Migalastat (Galafold)

• Manufacturer: Amicus Therapeutics
• Mechanism: Oral small-molecule pharmacological chaperone that binds to and stabilizes mutant α-Gal A, facilitating proper folding and trafficking to lysosomes[@germain2019]
• Dose: 123 mg every other day (on alternate days)
• Eligibility: Patients with amenable GLA gene mutations (approximately 35-50% of all Fabry patients)
• Efficacy: Demonstrated reduction in Gb3 in kidney interstitial capillaries; stabilization of renal function; reduction in cardiac mass; improvement in neuropathic pain[@hughes2017]
• Advantages: Oral administration; no risk of infusion reactions; no immunogenicity concerns
• Limitations: Only effective for patients with amenable mutations; requires genetic testing to confirm eligibility

Emerging Disease-Modifying Therapies

Gene Therapy

Gene therapy approaches for Fabry disease aim to deliver a functional GLA gene to restore endogenous α-Gal A production[@kohn2022]. Several clinical trials are ongoing:

• AAV-mediated gene delivery: Early-phase trials showing promising results with sustained α-Gal A expression
• lentiviral-based ex vivo gene therapy: Autologous hematopoietic stem cell transduction
• Current status: Phase I/II trials ongoing; long-term safety and efficacy data pending

Substrate Reduction Therapy

Research into substrate reduction therapy aims to reduce the production of Gb3 substrate rather than increasing its catabolism[@boyd2013]:

• Lucerastat (NCT03425539): Oral glucosylceramide synthase inhibitor; completed Phase III trials but did not meet primary endpoint
• Venglustat (NCT02446211): Similar approach; development discontinued for Fabry disease

Pegylated Formulated Enzyme (PEZ)

• Pegunigalsidase alfa (PRX-102): Pegylated form of α-Gal A with extended half-life
• Dose: 2 mg/kg every 4 weeks
• Phase III trials completed; demonstrates potential for less frequent dosing[@gokeralpan2021]

Symptomatic Management

Neuropathic Pain Management

Painful peripheral neuropathy is a hallmark of Fabry disease, resulting from small-fiber neuropathy due to Gb3 accumulation[@polymeropoulos2017].

First-Line Therapies

• Gabapentin: 900-2400 mg/day in divided doses
• Pregabalin: 150-600 mg/day in divided doses
• Carbamazepine: 200-1200 mg/day in divided doses (may exacerbate cardiac conduction issues)

Adjunctive Therapies

• Opioids: For severe, refractory pain (use with caution due to addiction potential)
• Topical therapies: Capsaicin cream, lidocaine patches
• Non-pharmacological: Physical therapy, acupuncture, cognitive behavioral therapy

Renal Management

Proteinuria Management

• ACE inhibitors (e.g., lisinopril, enalapril): First-line for proteinuria reduction
• ARBs (e.g., losartan, valsartan): Alternative or adjunct to ACE inhibitors
• Target: Reduce proteinuria to <0.5 g/day when possible

Renal Replacement Therapy

• Hemodialysis: Required when eGFR falls below 15 mL/min/1.73m²
• Peritoneal dialysis: Alternative option
• Renal transplantation: Effective in patients with end-stage renal disease; Gb3 accumulation may continue in other organs

Cardiac Management

Arrhythmia Management

• Antiarrhythmic medications: Amiodarone, sotalol for ventricular arrhythmias
• Pacemaker implantation: For patients with conduction abnormalities
• ICD implantation: For secondary prevention of sudden cardiac death in high-risk patients

Heart Failure Management

• Standard heart failure regimens: ACE inhibitors, ARBs, beta-blockers, diuretics
• Caution: Some standard heart failure medications may not be well-tolerated in Fabry cardiomyopathy

Cardiac Monitoring

• Annual echocardiogram
• Annual cardiac MRI with late gadolinium enhancement
• Regular ECG and Holter monitoring

Cerebrovascular Management

• Antiplatelet therapy: Low-dose aspirin or clopidogrel for stroke prevention
• Blood pressure control: Tight management of hypertension
• Statins: Consider for cardiovascular risk reduction
• anticoagulation: Warfarin or DOACs for patients with atrial fibrillation

Dermatological Management

• Angiokeratoma: Laser therapy, cryotherapy for symptomatic lesions
• Hypohidrosis: Skin moisturizers, environmental temperature control
• Telangiectasias: Laser therapy if symptomatic

Gastrointestinal Management

• Nausea/vomiting: Metoclopramide, ondansetron
• Diarrhea: Loperamide, clonidine
• Constipation: Fiber supplements, laxatives
• Early satiety: Small, frequent meals; prokinetic agents

Monitoring and Assessment

Baseline Evaluation

• Genetic testing: Confirm GLA mutation and identify amenable mutations for migalastat
• Enzyme activity: α-Gal A activity in plasma or leukocytes
• Biomarkers: Lyso-Gb3 (globotriaosylsphingosine) level
• Organ assessment:
• Renal: eGFR, proteinuria, kidney biopsy
• Cardiac: ECG, echocardiogram, cardiac MRI
• Neurological: Brain MRI, nerve conduction studies
• Ophthalmological: Slit-lamp examination

Ongoing Monitoring

Treatment Response Markers

• Lyso-Gb3 reduction: Reflects substrate clearance
• Renal function stabilization: Stable eGFR trajectory
• Cardiac mass reduction: Decreased left ventricular mass index
• Pain score improvement: Reduced neuropathic pain severity
• Quality of life: Patient-reported outcomes

Special Populations

Pediatric Patients

• ERT is approved for patients as young as 8 years (agalsidase beta) or 16 years (agalsidase alfa in Europe)
• Migalastat approved for patients ≥12 years with amenable mutations
• Dosing based on body weight
• Careful monitoring of growth and development

Pregnancy and Breastfeeding

• Pregnancy: ERT continuation generally recommended to prevent disease progression; discuss risks and benefits
• Breastfeeding: Limited data; ERT not recommended during breastfeeding
• Family planning: Genetic counseling important for affected females

Female Carriers

• Many females are symptomatic and require treatment
• Treatment decisions based on phenotype rather than genotype alone
• May have milder disease course but significant variability

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References